Protecting against threats and enabling rapid disease response: we face a big challenge

The COVID-19 pandemic has focussed our attention on the challenge of emerging infectious diseases for human health globally, and the need to develop strategies to respond rapidly and effectively.

At the same time, several important animal diseases, such as African swine fever, Lumpy skin disease and foot-and-mouth disease are increasing their geographical range, including into the Asia-Pacific region. In Australia we have also been dealing with an outbreak of Japanese encephalitis of unprecedented size, with impacts both animals and humans.

The Immune Resilience Future Science Platform is a CSIRO research and development program which aims to address these challenges.

Using new and emerging technologies, we will develop novel systems to stimulate, modulate and harness immune responses leading to the development of new strategies to enhance the immune resilience in both humans and animals.

Now, more than ever, we need to capitalise on new and emerging technologies to provide a deeper understanding of the innate and adaptive immune systems, our strongest defences against disease.

Our research will span three interconnected focus areas: vaccines, resilience technologies, and theranostics.


A scientist in a full biohazard suit looking through microscope lenses
  • Immune enhancers to improve vaccine efficacy and immune system priming or suppression
  • Novel and innovative vaccine platforms
  • Artificial intelligence, machine learning, and quantum for rational vaccine design

Resilience Technologies

Two men in blue shirts working with sheep in a sheep pen.
  • Precision Genome Engineering (PGE) platforms to develop resilient animals
  • Epigenetic reprogramming and trained immunity
  • Epithelial barriers and immunity


Two cells stained with fluorescent dye with bright blue dots surrounded by green.
  • Single cell immunology for vaccine design
  • Point of care devices
  • Forecasting response to vaccines and disease outcomes.